Cardarine (GW-501516) Liquid

Buy Cardarine GW-501516 Online

Cardarine, also known as GW-501516, is a PPAR-delta agonist that has become particularly popular for its association with fat metabolism, endurance, and energy utilization. Unlike SARMs, Cardarine does not work through the androgen receptor.

Product Information

GW-501516 was originally investigated as a PPAR-delta agonist for metabolic conditions. Research has shown that activating PPAR-delta can influence fatty-acid oxidation, lipid metabolism, and skeletal-muscle energy pathways.

How It Works

Cardarine activates PPAR-delta, a receptor involved in regulating how the body uses fats and carbohydrates for energy. This can increase pathways associated with fatty-acid oxidation and alter fuel utilization in skeletal muscle and other tissues.

Potential Benefits

1. Supports Fat Oxidation

Cardarine has been extensively studied for its ability to increase pathways involved in fatty-acid utilization.

2. Endurance Research

Its effects on skeletal-muscle energy metabolism have made Cardarine particularly popular in endurance-related research.

3. Supports Lipid Metabolism

Human research has demonstrated changes in triglycerides, LDL-related measures, and other lipid parameters following GW-501516 administration.

4. Supports Energy Utilization

PPAR-delta activation can shift skeletal-muscle metabolism toward greater reliance on fatty acids as an energy source.

5. Metabolic Research

Cardarine has also been studied in connection with insulin resistance, liver fat, and broader metabolic pathways.

Dosage

There is no approved therapeutic dosage for Cardarine. Published human studies have examined doses including 2.5–10 mg/day, while a forensic review notes that 10–20 mg/day has been reported in performance-enhancement use. These figures represent research or reported use rather than an established safe dosing protocol.

Side Effects

The long-term safety profile of Cardarine remains a major concern. Research has raised concerns surrounding tumor development, while other potential issues include changes in metabolic markers and unknown long-term effects.

References

Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GEO. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Molecular Endocrinology. 2003;17(12):2477-2493. PMID: 14525954. PubMed

Ooi EMM, Watts GF, Sprecher DL, Chan DC, Barrett PHR. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. Journal of Clinical Endocrinology & Metabolism. 2011;96(10):E1568-E1576. PMID: 21816786. PubMed

Please click here to see how purchases actually work on this site.